Diabetes as a risk factor for Alzheimer's disease: Insulin signalling impairment in the brain as an alternative model of Alzheimer's disease

Biochemical Society Transactions

Volumn 39, Issue 4, 2011, Pages 891-897

  Hölscher, Christian ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Alzheimer's disease (AD); Central nervous system (CNS); Glucagon like peptide 1 (GLP1); Insulin receptor substrate (IRS); Type 2 diabetes mellitus (T2DM)

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; COLONY STIMULATING FACTOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; GROWTH FACTOR; INCRETIN; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE; LIRAGLUTIDE; NERVE GROWTH FACTOR; PRESENILIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BLOOD BRAIN BARRIER; CELL PROLIFERATION; CELL REGENERATION; CLINICAL TRIAL (TOPIC); COGNITION; CONFERENCE PAPER; DENDRITIC CELL; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN METABOLISM; INSULIN SENSITIVITY; INSULIN SYNTHESIS; MEMORY; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVE FIBER GROWTH; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; RISK FACTOR; SIGNAL TRANSDUCTION; STEM CELL; STREPTOZOCIN DIABETES; UNSPECIFIED SIDE EFFECT;

ALZHEIMER DISEASE; ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION;

EID: 79960881826     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST0390891     Document Type: Conference Paper

References (87)

1. Hardy, J. (1997) Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20, 154-159
2. Hölscher, C. (2005) Development of β-amyloid-induced neurodegeneration in Alzheimer's disease and novel neuroprotective strategies. Rev. Neurosci. 16, 181-212
3. Luchsinger, J.A., Tang, M.X., Shea, S. and Mayeux, R. (2004) Hyperinsulinemia and risk of Alzheimer disease. Neurology 63, 1187-1192 (Pubitemid 39350015)
4. Ristow, M. (2004) Neurodegenerative disorders associated with diabetes mellitus. J. Mol. Med. 82, 510-529
5. Hoyer, S. (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol. 490, 115-125
6. Rasgon, N. and Jarvik, L. (2004) Insulin resistance, affective disorders, and Alzheimer's disease: review and hypothesis. J. Gerontol. A Biol. Sci. Med. Sci. 59, 178-183, discussion 184-192
7. Lebovitz, H.E. and Banerji, M.A. (2004) Treatment of insulin resistance in diabetes mellitus. Eur. J. Pharmacol. 490, 135-146
8. Carro, E. and Torres-Aleman, I. (2004) The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur. J. Pharmacol. 490, 127-133
9. Trudeau, F., Gagnon, S. and Massicotte, G. (2004) Hippocampal synaptic plasticity and glutamate receptor regulation: influences of diabetes mellitus. Eur. J. Pharmacol. 490, 177-186
10. Biessels, G.J., De Leeuw, F.E., Lindeboom, J., Barkhof, F. and Scheltens, P. (2006) Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. J. Neurol. Neurosurg. Psychiatry 77, 304-307
11. Stockhorst, U., de Fries, D., Steingrueber, H.J. and Scherbaum, W.A. (2004) Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans. Physiol. Behav. 83, 47-54
12. Gispen, W.H. and Biessels, G.J. (2000) Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci. 23, 542-549
13. Biessels, G.J., Bravenboer, B. and Gispen, W.H. (2004) Glucose, insulin and the brain: modulation of cognition and synaptic plasticity in health and disease: a preface. Eur. J. Pharmacol. 490, 1-4
14. Gault, V.A., Porter, W.D., Flatt, P.R. and Hölscher, C. (2010) Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet. Int. J. Obes. 34, 1341-1344
15. Carro, E. and Torres-Aleman, I. (2004) Insulin-like growth factor I and Alzheimer's disease: therapeutic prospects? Expert Rev. Neurother. 4, 79-86 (Pubitemid 38082126)
16. Moloney, A.M., Griffin, R.J., Timmons, S., O'Connor, R., Ravid, R. and O'Neill, C. (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 31, 224-243
17. Li, L. and Hölscher, C. (2007) Common pathological processes in Alzheimer disease and Type 2 diabetes: a review. Brain Res. Rev. 56, 384-402
18. Cohen, A.C., Tong, M., Wands, J.R. and de la Monte, S.M. (2007) Insulin and insulin-like growth factor resistance with neurodegeneration in an adult chronic ethanol exposure model. Alcohol. Clin. Exp. Res. 31, 1558-1573
19. van Dam, P. and Aleman, A. (2004) Insulin-like growth factor-I,cognition and brain aging. Eur.J.Pharmacol. 490, 87-95
20. Li, Z.G., Zhang, W. and Sima, A.A. (2007) Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 56, 1817-1824 (Pubitemid 47025451)
21. Carro, E. and Torres, A.I. (2004) The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur. J. Pharmacol. 490, 127-133
22. Watson, G.S. and Craft, S. (2004) Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur. J. Pharmacol. 490, 97-113
23. Zhao, W.Q., Chen, H., Quon, M.J. and Alkon, D.L.W. (2004) Insulin and the insulin receptor in experimental models of learning and memory. Eur. J. Pharmacol. 490, 71-81
24. Reger, M.A., Watson, G.S., Green, P.S., Baker, L.D., Cholerton, B., Fishel, M.A., Plymate, S.R., Cherrier, M.M., Schellenberg, G.D., Frey, II, W.H. and Craft, S. (2008) Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-β in memory-impaired older adults. J. Alzheimer's Dis. 13, 323-331
25. Okereke, O.I., Selkoe, D.J., Pollak, M.N., Stampfer, M.J., Hu, F.B., Hankinson, S.E. and Grodstein, F. (2008) A profile of impaired insulin degradation in relation to late-life cognitive decline: a preliminary investigation. Int. J. Geriatr. Psychiatry 24, 177-182
26. Reger, M.A., Watson, G.S., Green, P.S., Wilkinson, C.W., Baker, L.D., Cholerton, B., Fishel, M.A., Plymate, S.R., Breitner, J.C., DeGroodt, W. et al. (2008) Intranasal insulin improves cognition and modulates β-amyloid in early AD. Neurology 70, 440-448
27. Craft, S. (2007) Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr. Alzheimer Res. 4, 147-152
28. Craft, S., Baker, L.D., Green, P.S., Minoshima, S., Cross, D., Montine, T.J., Watson, G.S., Van Fossen, B., Bonner, L., Wilkinson, C.W. et al. (2010) A randomized, placebo-controlled trial of intranasal insulin in amnestic MCI and early Alzheimer's. Alzheimer's Dement. 6 (Suppl.), S587
29. Hallschmid, M. and Schultes, B. (2009) Central nervous insulin resistance: a promising target in the treatment of metabolic and cognitive disorders? Diabetologia 52, 2264-2269
30. Frias, J.P. and Edelman, S.V. (2007) Incretins and their role in the management of diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 14, 269-276
31. Gault, V.A., McClean, P.L., Irwin, N., Power, G.J., McCluskey, J.T. and Flatt, P.R. (2007) Effects of subchronic treatment with the long-acting glucose-dependent insulinotropic polypeptide receptor agonist, N-AcGIP, on glucose homeostasis in streptozotocin-induced diabetes. Pancreas 35, 73-79 (Pubitemid 46956204)
32. Perry, T. and Greig, N.H. (2005) Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr. Alzheimer Res. 2, 377-385
33. Goke, R., Larsen, P.J., Mikkelsen, J.D. and Sheikh, S.P. (1995) Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur. J. Neurosci. 7, 2294-2300
34. Hamilton, A. and Hölscher, C. (2009) Receptors for the insulin-like peptide GLP-1 are expressed on neurons in the CNS. NeuroReport 20, 1161-1166
35. Hölscher, C. and Li, L. (2010) New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease? Neurobiol. Aging 31, 1495-1502
36. Perfetti, R., Zhou, J., Doyle, M.E. and Egan, J.M. (2000) Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 141, 4600-4605 (Pubitemid 32055138)
37. Perry, T., Lahiri, D.K., Chen, D., Zhou, J., Shaw, K.T., Egan, J.M. and Greig, N.H. (2002) A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 300, 958-966
38. Perry, T., Lahiri, D.K., Sambamurti, K., Chen, D., Mattson, M.P., Egan, J.M. and Greig, N.H. (2003) Glucagon-like peptide-1 decreases endogenous amyloid-β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron. J. Neurosci. Res. 72, 603-612
39. Perry, T., Holloway, H.W., Weerasuriya, A., Mouton, P.R., Duffy, K., Mattison, J.A. and Greig, N.H. (2007) Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp. Neurol. 203, 293-301
40. During, M.J., Cao, L., Zuzga, D.S., Francis, J.S., Fitzsimons, H.L., Jiao, X., Bland, R.J., Klugmann, M., Banks, W.A., Drucker, D.J. and Haile, C.N. (2003) Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 9, 1173-1179
41. McClean, P., Pathasarthy, V., Faivre, E. and Hölscher, C. (2010) The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 31 6587-6594
42. Sugaya, K., Kwak, Y.D., Ohmitsu, O., Marutle, A., Greig, N.H. and Choumrina, E. (2007) Practical issues in stem cell therapy for Alzheimer's disease. Curr. Alzheimer Res. 4, 370-377
43. Gengler, S., McClean, P., McCurtin, R., Gault, V. and Hölscher, C. (2010) Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol. Aging, doi:10.1016/j.neurobiolaging.2010.02.014
44. Li, Y., Duffy, K., Ottinger, M., Ray, B., Bailey, J., Holloway, H., Tweedie, D., Perry, T., Mattson, M., Kapogiannis, D. et al. (2010) GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimer's Dis. 19, 1205-1219
45. Figueiredo, C.P., Pamplona, F.A., Mazzuco, T.L., Aguiar, Jr, A.S., Walz, R. and Prediger, R.D. (2010) Role of the glucose-dependent insulinotropic polypeptide and its receptor in the central nervous system: therapeutic potential in neurological diseases. Behav. Pharmacol. 21, 394-408
46. Blurton-Jones, M., Kitazawa, M., Martinez-Coria, H., Castello, N.A., Muller, F.J., Loring, J.F., Yamasaki, T.R., Poon, W.W., Green, K.N. and Laferla, F.M. (2009) Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 106, 13594-13599
47. Nagahara, A.H., Merrill, D.A., Coppola, G., Tsukada, S., Schroeder, B.E., Shaked, G.M., Wang, L., Blesch, A., Kim, A., Conner, J.M. et al. (2009) Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat. Med. 15, 331-337
48. Poon, W.W., Blurton-Jones, M., Tu, C.H., Feinberg, L.M., Chabrier, M.A., Harris, J.W., Jeon, N.L. and Cotman, C.W. (2011) β-Amyloid impairs axonal BDNF retrograde trafficking. Neurobiol. Aging 32, 821-833
49. Zuccato, C. and Cattaneo, E. (2009) Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 5, 311-322
50. Schulte-Herbruggen, O., Braun, A., Rochlitzer, S., Jockers-Scherubl, M.C. and Hellweg, R. (2007) Neurotrophic factors: a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases? Curr. Med. Chem. 14, 2318-2329
51. Clarris, H.J., Nurcombe, V., Small, D.H., Beyreuther, K. and Masters, C.L. (1994) Secretion of nerve growth factor from septum stimulates neurite outgrowth and release of the amyloid protein precursor of Alzheimer's disease from hippocampal explants. J. Neurosci. Res. 38, 248-258
52. Covaceuszach, S., Capsoni, S., Ugolini, G., Spirito, F., Vignone, D. and Cattaneo, A. (2009) Development of a non invasive NGF-based therapy for Alzheimer's disease. Curr. Alzheimer Res. 6, 158-170
53. Kordower, J.H., Mufson, E.J., Fox, N., Martel, L. and Emerich, D.F. (1997) Cellular delivery of NGF does not alter the expression of β-amyloid immunoreactivity in young or aged nonhuman primates. Exp. Neurol. 145, 586-591
54. Bradbury, J. (2005) Hope for AD with NGF gene-therapy trial. Lancet Neurol. 4, 335
55. Heese, K., Low, J.W. and Inoue, N. (2006) Nerve growth factor, neural stem cells and Alzheimer's disease. Neurosignals 15, 1-12 (Pubitemid 44131419)
56. Mueller, C. and Flotte, T.R. (2008) Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther. 15, 858-863 (Pubitemid 351712619)
57. Mandel, R.J. (2010) CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr. Opin. Mol. Ther. 12, 240-247
58. Shi, L., Linville, M.C., Tucker, E.W., Sonntag, W.E. and Brunso-Bechtold, J.K. (2005) Differential effects of aging and insulin-like growth factor-1 on synapses in CA1 of rat hippocampus. Cereb. Cortex 15, 571-577 (Pubitemid 40577473)
59. Nagano, I., Shiote, M., Murakami, T., Kamada, H., Hamakawa, Y., Matsubara, E., Yokoyama, M., Moritaz, K., Shoji, M. and Abe, K. (2005) Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurol. Res. 27, 768-772
60. Azzouz, M., Ralph, G.S., Storkebaum, E., Walmsley, L.E., Mitrophanous, K.A., Kingsman, S.M., Carmeliet, P. and Mazarakis, N.D. (2004) VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429, 413-417 (Pubitemid 38715132)
61. Hwang, D.H., Lee, H.J., Park, I.H., Seok, J.I., Kim, B.G., Joo, I.S. and Kim, S.U. (2009) Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice. Gene Ther. 16, 1234-1244
62. Lee, H.J., Kim, K.S., Park, I.H. and Kim, S.U. (2007) Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis and functional recovery in mouse stroke model. PLoS ONE 2, e156
63. Aubert-Pouessel, A., Venier-Julienne, M.C., Clavreul, A., Sergent, M., Jollivet, C., Montero-Menei, C.N., Garcion, E., Bibby, D.C., Menei, P. and Benoit, J.P. (2004) In vitro study of GDNF release from biodegradable PLGA microspheres. J. Controlled Release 95, 463-475
64. Gregory-Evans, K., Chang, F., Hodges, M.D. and Gregory-Evans, C.Y. (2009) Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration. Mol. Vision 15, 962-973
65. Sorenson, E.J., Windbank, A.J., Mandrekar, J.N., Bamlet, W.R., Appel, S.H., Armon, C., Barkhaus, P.E., Bosch, P., Boylan, K., David, W.S. et al. (2008) Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 71, 1770-1775
66. Terzi, D. and Zachariou, V. (2008) Adeno-associated virus-mediated gene delivery approaches for the treatment of CNS disorders. Biotechnol. J. 3, 1555-1563
67. Hölscher, C. (2010) Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Pat. CNS Drug Discovery 5, 109-117
68. Fernando, R.N., Larm, J., Albiston, A.L. and Chai, S.Y. (2005) Distribution and cellular localization of insulin-regulated aminopeptidase in the rat central nervous system. J. Comp. Neurol. 487, 372-390
69. Benomar, Y., Naour, N., Aubourg, A., Bailleux, V., Gertler, A., Djiane, J., Guerre-Millo, M. and Taouis, M. (2006) Insulin and leptin induce Glut4 plasma membrane translocation and glucose uptake in a human neuronal cell line by a phosphatidylinositol 3-kinase-dependent mechanism. Endocrinology 147, 2550-2556
70. Fernando, R.N., Albiston, A.L. and Chai, S.Y. (2008) The insulin-regulated aminopeptidase IRAP is colocalised with GLUT4 in the mouse hippocampus: potential role in modulation of glucose uptake in neurones? Eur. J. Neurosci. 28, 588-598 (Pubitemid 352040410)
71. Hoyer, S. (1997) Models of Alzheimer's disease: cellular and molecular aspects. J. Neural Transm. 49, 11-21
72. Zhao, A.Z., Shinohara, M.M., Huang, D., Shimizu, M., Eldar-Finkelman, H., Krebs, E.G., Beavo, J.A. and Bornfeldt, K.E. (2000) Leptin induces insulin-like signaling that antagonizes cAMP elevation by glucagon in hepatocytes. J. Biol. Chem. 275, 11348-11354
73. de la Monte, S.M. and Wands, J.R. (2006) Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J. Alzheimer's Dis. 9, 167-181
74. Hölscher, C. (1999) Synaptic plasticity and learning and memory: LTP and beyond. J. Neurosci. Res. 58, 62-75
75. Lin, J.W., Ju, W., Foster, K., Lee, S.H., Ahmadian, G., Wyszynski, M., Wang, Y.T. and Sheng, M. (2000) Distinct molecular mechanisms and divergent endocytotic pathways of AMPA receptor internalization. Nat. Neurosci. 3, 1282-1290
76. Wan, Q., Xiong, Z.G., Man, H.Y., Ackerley, C.A., Braunton, J., Lu, W.Y., Becker, L.E., MacDonald, J.F. and Wang, Y.T. (1997) Recruitment of functional GABAA receptors to postsynaptic domains by insulin. Nature 388, 686-690 (Pubitemid 27366441)
77. Schubert, M., Brazil, D.P., Burks, D.J., Kushner, J.A., Ye, J., Flint, C.L., Farhang, F.J., Dikkes, P., Warot, X.M., Rio, C. et al. (2003) Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J. Neurosci. 23, 7084-7092 (Pubitemid 36975873)
78. Eldar-Finkelman, H., Schreyer, S.A., Shinohara, M.M., LeBoeuf, R.C. and Krebs, E.G. (1999) Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. Diabetes 48, 1662-1666 (Pubitemid 29356878)
79. 2 with 2-aminobutyric acid. Arch. Biochem. Biophys. 428, 136-143
80. Doyle, M.E. and Egan, J.M. (2003) Pharmacological agents that directly modulate insulin secretion. Pharmacol. Rev. 55, 105-131
81. Zucker, R.S. (1999) Calcium- and activity-dependent synaptic plasticity. Curr. Opin. Neurobiol. 9, 305-313
82. + channel by stimulation of glutamate phosphoinositide-coupled receptors in cultured cerebellar granule cells. Eur. J. Neurosci. 3, 778-789
83. Lee, C.S., Sund, N.J., Vatamaniuk, M.Z., Matschinsky, F.M., Stoffers, D.A. and Kaestner, K.H. (2002) Foxa2 controls Pdx1 gene expression in pancreatic β-cells in vivo. Diabetes 51, 2546-2551 (Pubitemid 34827405)
84. Stoffers, D.A., Kieffer, T.J., Hussain, M.A., Drucker, D.J., Bonner-Weir, S., Habener, J.F. and Egan, J.M. (2000) Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49, 741-748 (Pubitemid 30339989)
85. Buteau, J., Roduit, R., Susini, S. and Prentki, M. (1999) Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in β (INS-1)-cells. Diabetologia 42, 856-864
86. Kawasaki, H., Springett, G.M., Mochizuki, N., Toki, S., Nakaya, M., Matsuda, M., Housman, D.E. and Graybiel, A.M. (1998) A family of cAMP-binding proteins that directly activate Rap1. Science 282, 2275-2279 (Pubitemid 29004080)
87. Leech, C.A., Holz, G.G., Chepurny, O. and Habener, J.F. (2000) Expression of cAMP-regulated guanine nucleotide exchange factors in pancreatic β-cells. Biochem. Biophys. Res. Commun. 278, 44-47